\n<\/p>\n
Scott Adams, the creator of the comic strip “Dilbert,” made headlines recently when he sought help for accessing a new cancer treatment. At 67, Adams shared in May that he is battling an advanced form of prostate cancer that has spread and is resistant to standard treatments.<\/p>\n
In a post on social media, he reached out to former President Donald Trump, requesting assistance in obtaining a drug called Pluvicto, which is designed for advanced prostate cancer patients. Adams mentioned that while his healthcare provider, Kaiser Permanente in Northern California, had approved the drug, there were delays in arranging the necessary IV infusion.<\/p>\n
“I’m declining fast,” Adams wrote. “I\u2019m asking President Trump if he can help get Kaiser to schedule it for me on Monday. That could give me a fighting chance to stay here a bit longer.”<\/p>\n
In response, Trump shared Adams’ message on social media, indicating he would look into the matter.<\/p>\n
Pluvicto, manufactured by Novartis AG, is a newer type of treatment that delivers targeted radiation to cancer cells, reducing the risk of harming healthy cells. It is known as radioligand therapy, which involves using a radioactive isotope to treat prostate cancer more effectively.<\/p>\n
Dr. Alan Bryce, an oncologist, explained that this method focuses the drug’s action on cancer cells, which not only helps control the disease but can also alleviate symptoms, giving patients more energy and reducing pain.<\/p>\n
Since its FDA approval in March 2022, Pluvicto has become the only radioligand therapy specifically approved for prostate cancer. It\u2019s typically given through an IV once every six weeks, up to six times, depending on the patient’s condition and response to the drug.<\/p>\n
Unfortunately, accessing Pluvicto can be challenging. There have been issues with the supply of the radioactive components used in the drug. Additionally, the handling of Pluvicto requires specialized care due to its radioactivity, which means it may not be available in all treatment facilities.<\/p>\n
Adams\u2019 situation highlights the importance of efficient medical systems that can provide timely treatment. His case indicates that while approval may have been granted, there can be delays that hinder access to life-saving medications.<\/p>\n
As with any treatment, Pluvicto can have side effects. Common experiences reported by patients include fatigue, dry mouth, and nausea. However, serious side effects, such as bleeding or infections, are possible but less common.<\/p>\n
Pluvicto is generally seen as having a more targeted impact compared to chemotherapy, which tends to have broader systemic effects.<\/p>\n
Prostate cancer remains a significant health concern, affecting about one in eight men in the U.S. It stands as the second leading cause of cancer-related deaths among men. With ongoing research and advancements like Pluvicto, there is hope for better outcomes for those diagnosed with this challenging disease.<\/p>\n\n","protected":false},"excerpt":{"rendered":"
Scott Adams Appeals for Cancer Treatment Help Scott Adams, the creator of the comic strip “Dilbert,” made headlines recently when he sought help for accessing a new cancer treatment. At 67, Adams shared in May that he is battling an advanced form of prostate cancer that has spread and is resistant to standard treatments. In<\/p>\n","protected":false},"author":1,"featured_media":20257,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[32],"tags":[5378,18866,1990,19,18595,18721,2073,23289],"class_list":{"0":"post-20256","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-cancer","9":"tag-cancer-research","10":"tag-health","11":"tag-lifestyle","12":"tag-medical-research","13":"tag-medications","14":"tag-mens-health","15":"tag-prostate-cancer"},"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/20256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=20256"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/20256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/20257"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=20256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=20256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=20256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}